RBC Capital raised the firm’s price target on PTC Therapeutics (PTCT) to $82 from $70 and keeps an Outperform rating on the shares after its Q3 earnings beat. The company’s Sephience launch appears to be off to an excellent start, likely surpassing the growing expectations into the quarter, and with signals supporting good near/medium-term durability, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $63 from $50 at TD Cowen
- PTC Therapeutics price target raised to $50 from $44 at Goldman Sachs
- PTC Therapeutics price target raised to $80 from $68 at JPMorgan
- PTC Therapeutics price target raised to $93 from $73 at Wells Fargo
- PTC Therapeutics price target raised to $68 from $46 at Barclays